Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AREBAG: Rebaudioside A in Type 2 Diabetes
NCT03510624Phase 1Completed
- Sponsor
- UZ Leuven
- Start
- Nov 2018
- Primary completion
- Apr 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rebaudioside A in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by UZ Leuven. Primary endpoint: Area under the curve blood glucose concentrations during an OGTT. Started Nov 2018; status: completed.
02
Drugs
rebaudioside A
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03510624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510624.